Cobolimab, CAS 2022215-65-0

Product Description: Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC)[1][2][3].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022./[2]Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81(10):1213-1219./[3]Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3(4):227-236. /[4]Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 2021 Sep;9(18):1447.

CAS Number: 2022215-65-0

Molecular Weight: N/A

Compound Purity: 95.0

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Tim3

• SKU: MEXHY-P99827-10
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-P99827-10
• Package Unit: 10 mg
• Quantity Unit: STK
• Conjugate: Unconjugated